Viewing nowCombinationEmpag Duo Extended Release Tablet 10/1000 mg (Empagliflozin, Metformin Hydrochloride)
Empagliflozin 10mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 202500685 · Approved 2025.03.25 · Insurance code 657309220
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood glucose control in adults with type 2 diabetes, in conjunction with diet and exercise. In particular, it helps to enhance blood glucose control efficacy when empagliflozin and metformin are administered together. For adult type 2 diabetes patients whose blood glucose is not well controlled and who have cardiovascular diseases, refer to the guidance of specialists regarding the impact on those patients. This medication effectively improves blood glucose control, assisting in diabetes management.
For antidiabetic therapy, the dose of this medicine should be determined by considering each patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: empagliflozin 25 mg and metformin hydrochloride extended-release 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily in the evening with a meal. To reduce gastrointestinal adverse reactions associated with metformin use, the metformin hydrochloride dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 25/1000 mg or 10/1000 mg extended-release tablet once daily. Patients taking the 12.5/1000 mg or 5/1000 mg extended-release tablet should take 2 tablets together once daily. For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial daily dose when taking this medicine is empagliflozin 10 mg plus the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. Patients switching from concomitant empagliflozin and metformin therapy to this medicine should receive their previous doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. No dose adjustment of this medicine is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], if well tolerated and not accompanied by other conditions that may increase the risk of lactic acidosis, this medicine may be used by adjusting the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to below 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, discontinue this medicine immediately. In patients aged 75 years or older, consider renal function and the risk of volume depletion.
This medication is used for treating diabetes and helps control blood glucose levels. However, it should not be administered to patients with impaired kidney function or liver dysfunction. Additionally, it should be avoided in situations such as acute infections, dehydration, heart diseases, and severe trauma. While taking this medication, there is a risk of hypoglycemia, so caution should be taken when used in combination with insulin or other hypoglycemic agents. Blood glucose levels and kidney function should be regularly monitored during treatment, especially in elderly patients or those with reduced kidney function. This medication can cause a rare but serious side effect known as lactic acidosis; therefore, if symptoms such as weakness, difficulty breathing, or abdominal pain occur, immediate medical attention should be sought. Also, there may be a risk of genital and urinary tract infections, so prompt treatment should be obtained if related symptoms appear. Discontinuation of this medication is required for a certain period when undergoing surgery or radiologic contrast examinations, and it should only be restarted once kidney function has returned to normal. The risk of side effects may increase when this medication is taken with alcohol, so avoiding alcohol is advisable. It is safer for pregnant women or those who may become pregnant not to use this medication, and it should be avoided during breastfeeding. When taking the medication, do not crush or chew the tablets; swallow them whole, although the coating may be visible in the stool, which is normal. During the treatment, symptoms of fluid loss or hypotension may occur, so preventing dehydration and ensuring adequate fluid intake is essential. Lastly, this medication's safety and efficacy have not been established in children, so it is recommended that it not be used in those under 18 years of age.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a sealed container. It is important to maintain a storage temperature between 1 to 30 degrees Celsius to ensure the medication's effectiveness and safety is preserved over time.
Light orange oval extended-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 10mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.